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Abstract
Background: Dietary supplementation with botanical oils that contain n-6 and n-3 eighteen carbon chain (18C)-PUFA
such as γ linolenic acid (GLA, 18:3n-6), stearidonic acid (SDA, 18:4n-3) and α linolenic acid (ALA, 18:3n-3) have been
shown to impact PUFA metabolism, alter inflammatory processes including arachidonic acid (AA) metabolism and
improve inflammatory disorders.
Methods: The diet of mild asthmatics patients was supplemented for three weeks with varying doses of two botanical
seed oils (borage oil [Borago officinalis, BO] and echium seed oil [Echium plantagineum; EO]) that contain SDA, ALA and
GLA. A three week wash out period followed. The impact of these dietary manipulations was evaluated for several
biochemical endpoints, including in vivo PUFA metabolism and ex vivo leukotriene generation from stimulated
leukocytes.
Results: Supplementation with several EO/BO combinations increased circulating 20–22 carbon (20–22C) PUFAs,
including eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and dihommo-gammalinolenic acid (DGLA),
which have been shown to inhibit AA metabolism and inflammation without impacting circulating AA levels. BO/EO
combinations also inhibited ex vivo leukotriene generation with some combinations attenuating cysteinyl leukotriene
generation in stimulated basophils by >50% and in stimulated neutrophils by >35%.
Conclusions: This study shows that dietary supplementation with BO/EO alters 20–22C PUFA levels and attenuates
leukotriene production in a manner consistent with a reduction in inflammation.
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Background
Asthma is a complex disease which involves smooth
muscle contraction and inflammation that result in
narrowing and obstruction of the airway. Arachidonic
acid (AA) metabolism via the 5-lipoxygenease pathway
to form leukotrienes has been demonstrated to be par-
ticularly important to the pathology of asthma. Specific-
ally, the cysteinyl leukotrienes, LTC4,L T D 4, and LTE4,
act at GPCRs, CysLT1R and CysLT2R, to elicit their
effects, which include contraction of bronchial smooth
muscle, vasodilatation, and mucus secretion within the
airways [1,2]. Additionally, LTB4 is a potent chemo-
attractant for granulocytes, effector T cells, and mono-
cytes, acting at a specific GPCR, BLT1 [3]. Collectively,
leukotrienes have numerous proinflammatory properties,
and leukotriene modifying drugs have proven effective in
the management of asthma [4] and allergic rhinitis [5].
In addition to pharmacologic modifiers, supplementa-
tion of diets with fatty acid-based marine and botanical oil
supplements have been demonstrated to reduce the sever-
ity of several inflammatory disorders including asthma.
One of the primary mechanisms thought to be responsible
for their efficacy has been the capacity of n-6 and n-3
polyunsaturated fatty acids to alter AA metabolism to
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with fish oils that contain eicosapentaenoic acid (EPA;
20:5, n-3) inhibits leukotriene generation, likely through
substrate competition of EPA with AA for the action of
cytosolic phospholipase A2 and 5-lipoxygenase [6].
In regard to botanical oils, borage seed oils contain the
18 carbon PUFA, gammalinolenic acid (GLA; 18:3, n-6)
that is elongated by most tissues and inflammatory cells to
dihommo-gammalinolenic acid (DGLA) (Figure 1). Newly-
formed DGLA is then incorporated into membrane phos-
pholipids. Like EPA, DGLA has the capacity to compete
with AA for eicosanoid production. DGLA is also
converted to prostaglandin (PG)H1 via cyclooxygenase en-
zyme(s), which is then converted to PGE1.P G E 1 has been
illustrated to have anti-inflammatory effect in both animals
and humans [7-9].
In addition, seed oil from another member of the
Boraginaceae family, Echium plantagineum contains both
n-6 and n-3 18C-PUFAs, including a GLA, α-linolenic acid
(ALA; 18:3, n-3) and stearidonic acid (SDA; 18:4, n-3). The
conversion of ALA to EPA and DHA is poor in humans
[10], which is believed to be a result of the inefficiency of
the initial rate-limiting step (Δ-6 desaturase, FADS2 gene)
involved in 20–22 carbon PUFA biosynthesis. However
SDA is downstream of Δ-6 desaturase and is 4 to 5-fold
more efficiently converted to EPA than ALA [11].
Additionally, SDA has been demonstrated to block in vitro
leukotriene generation and in vivo inflammatory processes
(reviewed in [11]).
It has been long appreciated that natural products may
contain a complex mixture of several active ingredients
with synergistic biological effects. As discussed above, bo-
tanical seed oils contain several 18C-PUFAs that have the
potential to impact diseases that are driven by eicosanoid
generation. Several studies have examined the impact of
providing individual botanical oils that contain a high pro-
portion of their total fatty acids as a putative PUFA active
ingredient; however, little is known regarding the bio-
chemical interactions of adding more than one botanical
oil containing several potential PUFA active ingredients.
The primary objective of this current study was to exam-
ine the biochemical impact of adding PUFAs found in two
botanical seed oils on PUFA metabolism and leukotriene
generation in mild asthmatic patients.
Materials and methods
Subjects
Thirty-seven asthmatic subjects (ages 18–64) were
recruited. Written informed consent was obtained from
all subjects prior to enrollment. Asthma was diagnosed by
the presence of variable airflow obstruction or by a history
of treatment for asthma with documented airways hyper-
responsiveness to methacholine [12]. Histories (medical
and respiratory), a brief physical examination and routine
clinical test were used to exclude the presence of signifi-
cant co-morbid diseases. The inclusion criteria were: 1)
male or female 18 years to 65 years of age; 2) asthma with
FEV1 50 to 90% of predicted, or personal best; and 3)
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Figure 1 Pathways for metabolism of n-6 (left) and n-3 (right) PUFAs in humans. The pathway depicts the synthesis of 20 and 22 carbon
PUFAs from the essential, dietary PUFAs, α-linolenic acid (n-3) and linoleic acid (n-6). The PUFAs derived from borage oil (linoleic and gamma-
linolenic acids, both n-6) and echium (α-linolenic, n-3; stearidonic, n-3; linoleic and gamma-linolenic acids, both n-6) would be expected to enter
the pathways at the indicated points.
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beta-2 agonist. The exclusion criteria were: 1) pregnant or
nursing; 2) smoking history of>10 pack years or active
smoking within the previous year; 3) use of asthma treat-
ments that potentially alter leukotriene biosynthesis includ-
ing theophylline and oral steroids; 4) dietary supplements
with fatty acids or other products that may interfere with
leukotriene generation; 5) treatment within the previous
three months with omalizumab (monoclonal antibody di-
rected against IgE); 6) use of non-steroidal anti-
inflammatory drugs in the week prior to any measurements
of ex vivo leukotriene generation; 7) a history of aspirin-
sensitive asthma; 8) significant abnormalities in CBC, differ-
ential white cell count, renal function, and liver function, or
urinalysis; and 9) any serious co-morbid medical condition.
Subjects meeting the entry criteria were randomized
to one of the four study groups based on botanical oil
dosing (Table 1). Subjects used rescue albuterol less than
twice a week, had nocturnal asthma less than twice a
month, and had a forced expiratory volume in one sec-
ond ≥75% predicted. During the month prior to entry
into the study, no subject used leukotriene modifiers,
oral or high dose inhaled steroids, or theophylline, and
for three months prior to entry into the study no subject
used omalizumab, a monoclonal antibody against IgE.
The study was approved by the Partners Human Sub-
jects Research Committee. An investigator-initiated IND
was obtained from the Food and Drug Administration
(IND number 74,110). Because the outcomes in this
study were entirely biochemical with no assessment
of clinical efficacy, the study was not registered at
clinicaltrials.gov.
Dietary fatty acids
Capsules containing echium seed oil (1000 mg) or borage
seed oil (1300 mg) were supplied by Bioriginal (Saskatoon,
SA, Canada). The fatty acid contents of the oils were vali-
dated by gas chromatography (Table 2). Since the leaves of
Echium plantagineum contain pyrrolizidine alkaloid, an in-
dependent assay of this toxin was obtained, assessed by
high performance TLC, and found it to be less than 4 ng/g
of oil (Chemisches Laboratorium Dr. Hermann Ulex Nachf,
Hamburg-Norderstedt, Germany).
Study design
The study goal was to test combinations of Boraginaceae
family seed oils derived from Borago officinalis (BO) and
Echium plantagineum L. (EO) for their capacity to impact
circulating PUFA levels and inhibit ex vivo leukotriene
generation. After baseline determinations of plasma fatty
acid levels and ex vivo leukotriene generation, subjects
were randomized to dosing groups (Table 1) ingesting a
Table 1 Study group compositions and daily dosing
scheme for borage and echium seed oils in the four
groups of subjects
Group 1 Group 2 Group 3 Group 4
No. of Subjects 691 1 1 1
(female) (3) (5) (6) (7)
Age (range) 22–46 18–54 19–58 22–64
No. of subjects withdrawn 1112
Echium Oil Dose (g) 1 4 742
No. of daily capsules 14 7 4 2
ALA (g) 4.02 2.01 1.15 0.57
SDA (g) 1.75 0.875 0.5 0.25
GLA (g) 1.54 0.77 0.44 0.22
Borage Oil Dose (g) 0 3.9 5.2 5.2
No. of daily capsules 0344
ALA (g) <0.01 <0.01 <0.01 <0.01
S D A ( g ) 0000
GLA (g) 0 0.9 1.2 1.2
Total
No. of daily capsules 14 10 8 6
ALA (g) 4.02 2.01 1.15 0.57
SDA (g) 1.75 0.875 0.5 0.25
GLA (g) 1.54 1.67 1.64 1.44
The number of daily capsules, containing 1 g (EO) or 1.3 g (BO) oil per capsule,
and the amount of ALA, SDA and GLA provided by the encapsulated echium
and borage oils is shown for each dosing group. Recruitment into Group 1
was stopped after the interim analyses showed that the highest dose of EO
was not required to prevent elevations of AA levels in circulating plasma.
Table 2 Fatty acid profile of botanical oils consumed by
asthmatic subjects
% of Total Fatty Acids
Fatty acid Echium Borage
C16:0 7 6.7
C16:1 0.2 0.2
C18:0 4.1 3.3
C18:1 16.8 10.4
C18:2 n-6 18 24.6
C18:3 n-6 10.8 40.5
C18:3 n-3 28.7 0.1
C18:4 n-3 12.5 0.3
C20:0 0.2 0.3
C20:1 0.7 5.2
C20:1 0 0.3
C22:0 0 0.6
C22:1 0.4 3.8
C24:0 0 0.1
C24:1 0 3.1
Others 0.3 0.5
Total 99.7 100
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and 0.57 g to 4.02 g ALA in divided doses (three times a
day) for 3 weeks.
Aside from the addition of supplements, the subject’s
diets were not altered before or during the study. The
‘typical’ western diet provides very small quantities of
GLA and SDA, and it is difficult to measure these PUFA
in circulating or cellular lipids. GLA and SDA are typic-
ally only observed when individuals are consuming a
GLA- or SDA- containing supplement such as borage,
evening primrose, black currant, or echium, and this was an
exclusion criterion of the study. ALA (n-3) makes up ~1%
of the typical western diet and so the supplement may have
some impact on dietary levels. Approximately 7% of energy
in the western diet is LA, and thus the quantities of
LA in the supplements would have little total impact
on overall linoleic acid (n-6) consumption.
Concentrations of GLA provided to human subjects as
borage oil alone have been shown to induce increases in
circulating AA levels [13]. It was our hypothesis that the
presence of the n-3 18C-PUFA SDA in echium oil would
prevent such an increase. However, to assure that there
were no elevations of circulating AA out of the normal
range, an interim analysis was carried out during the early
phase of the study. The interim analyses revealed that AA
levels remained constant in all groups and consequently,
the study was then completed. Blood and urine were col-
lected weekly for assessment of hematological indices,
liver and renal function, plasma fatty acids, ex vivo leuko-
triene generation. After three weeks of supplementation,
subjects entered a 3 week wash-out phase, in which
plasma fatty acids and ex vivo leukotriene generation were
measured weekly. After dropouts, 6 to 11 individuals com-
pleted each arm of the study.
Subjects reported any change in their medical condi-
tion at each study visit and used diary cards to record all
medical symptoms and to log intake of study oils. Com-
pliance was monitored by medication diaries and counts
of returned capsules. These assessments indicated at
least 90% compliance by all subjects and plasma fatty
acids measurements, in which no outliers were seen, also
reflected in a comparable adherence to the supplementa-
tion. As the end points of the study were entirely bio-
chemical, the subjects were not blinded (i.e. subjects
took different numbers of capsules depending on the
group to which they were assigned). The objective of this
biochemical study was to determine the impact of po-
tentially bioactive PUFAs in combinations of BO and EO
on plasma fatty acid levels and ex vivo leukotriene pro-
duction. All individuals performing the biochemical as-
says were blinded to the subjects’ study group.
The most common adverse events associated with taking
BO/EO combinations were gastrointestinal symptoms, oc-
curring in thirteen subjects, variously reported as gas,
constipation, loose stools, and/or abdominal pain or dis-
comfort. With the exception of the 3 subjects who with-
drew due to gastrointestinal discomfort (Groups 2, 3 and
4), these symptoms were mild and transient, occurred in
the first few days of the study and resolved within 2 to
3 days while still taking BO/EO combinations. Other ad-
verse events included cold-like symptoms (n=7: Group 1
n=3 ;G r o u p2 ,n=2 ;G r o u p3 ,n=1 ;G r o u p4 ,n=1) ,p h a -
ryngitis (n=2; one each in Groups 2 and 4), mild symp-
toms of asthma associated with seasonal allergies (n =2,
one each in Groups 3 and 4), transient wrist pain (n =1;
group 3), and transient itchy rash (n=1; Group 4). Two
other subjects withdrew from the study due to the develop-
ment of itch and mild asthma flare (Group 4) and unfore-
seen extension of an out-of-town business trip (Group 1).
There were no significant changes in vital signs in any
study subjects.
There were no consistent or significant changes in bio-
chemical laboratory parameters or urinalysis during the
study (data not shown). However, in four of the individ-
uals who entered the study (2 male, 2 female) there was a
decrease in circulating hemoglobin of >1.0 g/dl. Across all
study groups there was on average a decrease in circulat-
ing hemoglobin of 0.45 g/dl (13.8 to 13.3 g/dl; p<0.001),
which did not vary significantly between study groups
(p=0.09 for differences among groups across time). In
three individuals, the value dipped just below the range of
normal. There was an accompanying decrease in red cell
count from 4.58 to 4.39x10
12 /liter with no change in
mean corpuscular volume. A decrease in hemoglobin
concentration was not seen in all subjects. There were
no accompanying decreases in white cell count or
platelet count.
Plasma and botanical oil fatty acids analysis
Fatty acid methyl esters were prepared in duplicate
plasma samples (100 μl) following a modification of
Metcalfe et al. [14] and analyzed by gas chromatography
as previously described [15]. Encapsulated oils were suit-
ably diluted in hexane and submitted to fatty acid ana-
lysis in a manner comparable to that for plasma. Fatty
acids in sample were identified based on retention times
of authentic fatty acid methyl esters (Supleco, Bellefonte,
PA, USA; Cayman Chemicals, Ann Arbor MI, USA;
Matreya, Pleasant Gap PA, USA; NuChek Prep, Elysian,
MN, USA).
Ex vivo leukotriene generation
FcεRI-dependent generation of cysteinyl leukotrienes from
basophils. Peripheral blood mononuclear cells (PBMC),
typically containing ~3 to 4% basophils, were isolated
from 20 mL of blood by density gradient centrifugation
over Percoll (GE Healthcare, Piscataway, NJ) as de-
scribed [16]. As previously described [16], basophils
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affinity Fc receptor for IgE (FcεRI). Under these circum-
stances, the basophil is the predominant, if not the only,
source of cysteinyl leukotrienes. Briefly, cells were
primed with 10 μg/L IL-3 on ice and stimulated with
0.01 to 1.0 μg/mL of 15A5, an activating monoclonal
antibody to FcεRI, for 30 min at 37°C. Cysteinyl leukotri-
enes in the supernatant fluids were stored at −80°C until
assayed by immunoassay (Cayman Chemical Company,
Ann Arbor, MI or GE Healthcare) for LTC4 with 100%
cross-reactivity with LTC5, 48% and 46% cross-reactivity
with LTD4 and LTD5, respectively, and <10% cross-
reactivity with LTE4 and LTE5.
A23187-stimulated generation of leukotrienes from neu-
trophils. Neutrophils were isolated from heparinized blood
by dextran sedimentation, density gradient centrifugation
through Ficoll Paque (GE Healthcare, Uppsala, Sweden),
and hypotonic lysis of contaminating red cells [17]. Neu-
trophils (2 × 10
6) were stimulated (5 min, 37°C) with 0.1
to 10 μmol/L A23187 (Sigma-Aldrich, St Louis, MO) in
Hanks buffered salt solution containing 1.25 mmol/L cal-
cium and magnesium salts, 25 mmol/L Hepes, and 1 g/L
fatty acid-free bovine serum albumin. Leukotrienes in the
supernatants were resolved by reverse-phase HPLC (RP-
HPLC) as described [18] and quantified by absorbance
at 280 nm (LTB4 and all-trans LTB4)a n d2 3 5n m( 5 -
hydroxyeicosatetraenoic acid, 5-HETE).
Statistical analysis
Statistical analyses were performed using SAS Version
9.2. We employed a repeated measures mixed model
(rmm) analysis for each fatty acid to predict the response
in which repeated measures were taken on each subject
at each visit (time) and the group and time interactions
were modeled along with the main effects. The model
utilized a compound symmetry correlation structure
since the correlation between pairs of times would be
similar and not expected to change across time. For ana-
lyses of ex vivo leukotriene generation by neutrophils
and basophils, we also considered the effect of a range
of doses of each stimulus at each visit within the same
modeling. We then used adjusted least square mean dif-
ferences obtained from each rmm model to compare the
differences between groups and between times within a
single group. All analyses were conducted at a 0.05 level
of significance.
Results
Plasma fatty acids
The effects of dietary supplementation with BO and EO
on n-3 and n-6 PUFA levels are provided in Figure 2 and
Figure 3, respectively. ALA (18:3n-3), present in echium
oil, tended to increase in all groups during the supplemen-
tation period (weeks 1–3) and was significantly higher
(p<0.05, Figure 2, white bar) than baseline in Group 1
(wk 3) and Group 3 (wk 2). SDA (18:4n-3) was not detect-
able in the plasma at baseline but rose significantly during
supplementation with BO and EO (p<0.0001, Figure 2,
black bar). As expected, the increase in plasma SDA varied
between groups and was most marked in Group 1 in
which subjects consumed the largest dose of echium oil
(p=0.004 for differences among groups across time). In
each group, the plasma levels of EPA (20:5n-3; Figure 2,
gray bar) and its elongation product DPA (22:5n-3;
Figure 2, cross-hatched bar) rose significantly (p<0.0001
for each fatty acid) in a manner that was dependent on
the dose of echium oil ingested (p=0.004 for group by
time interactions for each fatty acid). However, there was
no rise in circulating plasma DHA (22:6n-3; Figure 2,
white striped bar) in any group (p=0.14). During the
washout phase, plasma SDA, EPA and DPA rapidly
returned to baseline levels.
With respect to n-6 fatty acids, plasma concentrations
of GLA (18:3n-6; Figure 3, black bar) and DGLA (20:3n-6;
Figure 3, white bar) rose in each group (p<0.0001 for
each fatty acid) with no significant difference between
groups (p=0.06 and p=0.63, respectively, for differences
among groups across time). Importantly, concentrations
of plasma AA (20:4n-6; Figure 3, gray bar) remained con-
stant throughout with no significant change during sup-
plementation with BO and EO in any group (p=0.39 for
effect of time, and p=0.87 for group by time interactions).
During the washout phase, plasma GLA and DGLA rap-
idly returned to baseline levels.
Ex vivo leukotriene generation
Figure 4 illustrates the effect of dietary supplementation
with a constant dose of BO and variable doses of EO on
ex vivo cysteinyl leukotriene generation from basophils
stimulated through FcεRI. Basophils are the only cell
among peripheral blood mononuclear cells that express
the fully functional heterotetrameric αβγ2 form of FcεRI
and are the principal, if not the only, source of cysteinyl
leukotrienes when this population of cells is stimulated
through this receptor [16]. We therefore stimulated baso-
phils at ~3 to 4% purity in PBMC with an activating anti-
body to FcεRI, before (baseline) and at weekly intervals for
three weeks while subjects supplemented their diet with
borage and echium seed oils. Because of the marked dif-
ference among individuals in absolute quantities of
cysteinyl leukotrienes generated by basophils, varying
from 1 to 90 ng/10
6 basophils, data are expressed as a per-
centage of maximal leukotriene generation per million ba-
sophils prior to treatment with BO and EO. Compared to
baseline leukotriene generation (Figure 4, closed circles),
supplementation with BO and EO resulted in decreased
FcεRI-mediated leukotriene generation. This inhibitory
effect was statistically significant in all groups during
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difference between study groups (p<0.0001 for differ-
ences among groups across time). The most stable and ro-
bust inhibition of leukotriene generation was seen in
Group 2 (Figure 4), in which individuals ingested EO/BO
combination that provided 1.7 g of GLA, 2.01 g ALA and
0.9 g SDA daily. In this group there was a time-dependent
inhibition of cysteinyl leukotriene generation from baso-
phils, stimulated with all concentrations of the antibody to
FcεRI that reached 57% and 50% inhibition of the maximal
response by weeks 2 and 3, respectively. A similar inhib-
ition of FcεRI-dependent cysteinyl leukotriene generation
was observed in Group 3 (Figure 4) in which individuals
ingested a BO/EO combination that provided 1.6 g of
GLA, 1.15 g ALA and 0.5 g SDA daily (n=8). In Group 3,
inhibition was maximal (60%) at week one and cysteinyl
leukotriene generation remained suppressed at weeks 2
and 3. Inhibition of FcεRI-dependent cysteinyl leukotriene
generation from peripheral blood basophils was less ro-
bust in Groups 1 and 4.
The inhibitory effect of dietary BO and EO on baso-
philic leukotriene generation was transient. Figure 5
shows the reversal of ex vivo cysteinyl leukotriene gener-
ation from basophils (stimulated with a maximum con-
centration of stimulating antibody) during the washout
period after individuals stopped taking capsules of bor-
age and echium oil supplements. Data are expressed as
percentage of the maximum cysteinyl leukotriene gener-
ation prior to starting supplements. In all groups, there
was a return to baseline values within 3 weeks.
A23187 is a calcium ionophore that stimulates leukotri-
ene generation by eliciting calcium flux in a receptor-
independent manner. In neutrophils, it provides a robust
stimulus for leukotriene generation and allows assessment
of the integrity of the whole leukotriene biosynthetic path-
way including the terminal product, LTB4, and the stable
non-enzymatic degradation products of its intermediates,
5-HETE (from 5-hydroperoxyeicosatetraenoic acid) and
all-trans-LTB4 (from LTA4). We therefore examined the
effects of dietary supplementation with BO and EO on
A23187-stimulated leukotriene generation from neutro-
phils. The shape and position of the dose response curves
for release of LTB4 and 5-HETE were similar at baseline,
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Figure 2 Effects of dietary supplementation with borage and
echium seed oils on concentrations of plasma n-3 fatty acids.
Data are expressed as a percentage of total plasma fatty acids and
are shown for ALA (open bar), SDA (black bars), EPA (gray bars), DPA
(cross-hatched bars), and DHA (white striped bars). Fatty acid profiles
were monitored during the time course of the study beginning at
baseline (Pre), during supplementation (weeks 1–3) and during the
washout phase (w/o1-3). Data are mean± SEM for each group.
Statistically significant rises in SDA, EPA and DPA were noted over
time (p< 0.0001) with significant differences among
groups (p=0.004).
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dietary supplementation with BO and EO were similar
(data not shown). Therefore, data are presented as total
leukotriene generation; i.e. the sum of 5-HETE, LTB4,a n d
all-trans-LTB4. A23187 elicited the dose-dependent re-
lease of leukotrienes that was apparent at a concentration
of 0.3 μM and reached a maximum response at a concen-
tration of 3 to 10 μM A23187 (Figure 6). The quantities of
all-trans LTB4 diastereoisomers that were generated were
small and were not always readily measured by UV ab-
sorbance; they are included in the data where possible.
Treatment with BO/EO combinations led to a significant
inhibition of A23187-stimulated leukotriene generation
from neutrophils (p<0.0001) with a significant difference
in effect between groups (p=0.02 for differences among
groups across time). The group-dependent effects of diet-
ary supplementation with BO and EO on A23187-
stimulated leukotriene generation from neutrophils were
similar to those observed for FcεRI-dependent cysteinyl
leukotriene generation from basophils (Figure 4). The
greatest effect was seen in Group 2 (Figure 6), in which
maximal total leukotriene generation was inhibited 43%
after three weeks of dietary supplementation with BO/EO
combinations. The inhibitory effect of the dietary supple-
mentation on neutrophil leukotriene generation declined
over time in Group 3 and was less robust in Group 4
(Figure 6). As in the case of basophils, A23187-stimulated
leukotriene generation from neutrophils returned to base-
line during the 3-week wash-out period (data not shown).
Discussion
Botanical seed oils from plants such as borage and
echium have shown modest efficacy in a number of ani-
mal and human inflammation models and disease. These
botanicals contain 18C-PUFAs (ALA, SDA and GLA)
that can be metabolized into 20–22 carbon PUFAs such
as EPA, DHA, DGLA and AA. All of these have been
shown to impact eicosanoid generation. However, a bet-
ter understanding of the in vivo biochemistry of poten-
tially bioactive PUFAs found in these botanical seed oils
and oil combinations and their capacity to block inflam-
matory processes including eicosanoid production is
needed to enhance the effectiveness of botanical seed
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Figure 3 Effects of dietary supplementation with borage and
echium seed oils on concentrations of plasma n-6 fatty acids.
Data are expressed as a percentage of total plasma fatty acids and
are shown for GLA (black bars), DGLA (white bars), and AA (gray
bars). Fatty acid profiles were monitored during the time course of
the study beginning at baseline (Pre), during supplementation
(weeks 1–3) and during the washout phase (w/o1-3). Data are mean
±SEM for each group. Statistically significant rises in GLA and DGLA
were noted over time (p<0.0001) with no statistically significant
differences among groups.
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http://www.lipidworld.com/content/12/1/141oils. The current study utilized various BO/EO combina-
tions to understand these processes.
Supplementation with BO/EO combinations increases
plasma levels of n-3 and n-6, 18 carbon and 20–22 carbon
PUFAs during the supplementation periods (Figure 2 and
Figure 3). Of note, circulating levels of three PUFAs,
DGLA, EPA and DPA increased after supplementation. It
is likely that DGLA increased as a result of GLA found in
both BO and EO. As discussed above, GLA is readily elon-
gated to DGLA in cells and tissues utilizing an enzyme
encoded for by a gene known as elongase 5 (ELOVL5).
Once formed, DGLA is incorporated into inflammatory
cells and tissues and competes with AA for the action
of cytosolic phospholipase A2 and cyclooxygenase to
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Figure 5 Cessation of dietary supplementation reverses
inhibition of FcεRI-dependent cysteinyl leukotriene generation
by peripheral blood basophils. After 3 weeks of dietary
supplementation (open bars), subjects stopped ingesting borage
and echium seed oils. FcεRI-stimulated basophilic cysteinyl
leukotriene generation was measured at one (gray bar), two
(cross-hatched bar) and three weeks (solid bar) of washout. Data are
shown for maximal cysteinyl leukotriene generation in response to
1.0 μg/ml 15A5. Data are expressed as a percentage of maximal
cysteinyl leukotriene generation in each subject and are expressed
as means±SEM.
Figure 4 Dietary supplementation with borage and echium
seed oils decreases FcεRI-dependent cysteinyl leukotriene
generation by peripheral blood basophils. Cysteinyl leukotriene
generation is shown prior to (●, closed circles) and one week
(Δ, open triangles), two weeks (□, open squares), and three weeks
(○, open circles) after dietary supplementation with one of four
borage and echium seed oil combinations (Groups 1–4, respectively)
in response to buffer alone, control IgG1 (1.0 μg/ml, IgG), and 15A5,
an activating antibody against FcεRI (0.01 to 1.0 μg/ml). Due to
technical errors, data are not available for one subject in each of
groups 1, 3, and 4. In addition, basophils from one subject in each
of groups 3 and 4 failed to release leukotrienes upon stimulation, a
well described phenomenon due to impaired signaling through Syk.
Data are expressed as a percentage of maximal cysteinyl leukotriene
generation in each subject and are expressed as means± SEM.
Statistically significant suppression of ex vivo leukotriene generation
was noted (p<0.0001) with a significant difference between groups
(p<0.0001).
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http://www.lipidworld.com/content/12/1/141form PGE1. Additionally DGLA is converted to a 15-
lipoxygenase product, 15-hydroxyeicosatrienoic acid
(15 HeTrE) by human mononuclear leukocytes [18].
15-HETrE has been demonstrated to be a potent
blocker of LTB4 formation.
Additionally this botanical oil combination increased
circulating levels of EPA and DPA This contribution was
like due to EO addition since it contains the precursor
PUFAs, ALA and SDA. Providing 0.25 g/d to 1.75 g/d of
SDA and 0.57 g/d to 4.02 g/d of ALA from EO led to
significant and dose-dependent increases in circulating
EPA and DPA; plasma EPA concentrations rose more
than 2-fold in the group receiving the highest concentra-
tion of SDA (Figure 2). This increase in EPA and DPA is
likely a result of SDA and not ALA as in vivo SDA con-
version to EPA is 4–5 fold more efficient than ALA.
However, some epidemiological studies suggest that
ALA-containing oils (from seed oils such as flax; Linum
usitatissimum L.) [19] may provide independent protec-
tion from cardiovascular disease.
Numerous studies show the biological impact of EPA
and DPA. EPA reduces AA metabolism through several
mechanisms including decreasing AA mobilization from
membrane phospholipids, competition for cylooxygenase
and 5-lipoxygenease and reducing the expression of AA
metabolizing enzymes and proinflammatory cytokines.
Additionally, EPA can serve as a substrate for prostaglan-
din formation generating “3-series” prostaglandin products
including PGD3,P G E 3,P G F 3α,P G I 3,a n dT x A 3 and “5
series” leukotriene products including LTB5 and LTC5
[20]. Reduced asthma symptoms with n-3 PUFA ingestion
have been shown to be related to 5-series leukotriene
production [21]. With regard to inflammation, DPA is
beginning to receive attention. DPA is converted to 11-
hydroxy-7,9,13,16,19-DPA and 14-hydroxy7,10,12,16,19-
DPA, which inhibit aggregation of platelets and contain
10-fold greater capacity to elicit endothelial cell migration
than EPA, a biological process critical to wound healing
[22,23]. There were no changes in plasma levels of DHA,
likely reflecting the poor bioconversion of EPA to DHA.
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Figure 6 Dietary supplementation with borage and echium oils
decreases A23187-stimulated total leukotriene generation by
peripheral blood neutrophil. Leukotriene generation is shown
prior to (●, closed circles) and one week (Δ, open triangles), two
weeks (□, open squares), and three weeks (○, open circles) after
dietary supplementation with one of four borage and echium seed
oil combinations (Groups 1–4, respectively) in response to buffer
alone and increasing concentrations of the calcium ionophore,
A23187 (0.1 to 10 μM). Total leukotriene generation is the sum of
LTB4, 5-HETE, and, where measurable, all-trans-LTB4 isomers. Data are
expressed as means±SEM. Statistically significant suppression of
ex vivo leukotriene generation was noted (p< 0.0001) with a
significant difference in effect between groups (p=0.02).
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such as BO have the potential to increase circulating AA
which could enhance inflammation and platelet aggrega-
tion through increased thromboxane formation [24].
However, there were no changes in AA levels as a result
of BO/EO supplementation. It is possible that the ob-
served increase in EPA resulting from of the botanical
combination is a feedback inhibitor of AA production
via the Δ5 desaturation step. EPA has been demon-
strated to inhibit the in vivo and in vitro desaturation of
DGLA to form AA [25,26]. In any event, the BO/EO
combination led to an increase in three 20–22 carbon
PUFAs, DGLA, EPA and DPA that have been demon-
strated to inhibit AA metabolism and attenuate inflam-
mation without increasing circulating levels of AA.
The final objective of this paper was to determine
whether these botanical oil combinations had the capacity
to inhibit leukotriene generation from two inflammatory
cells, basophils and neutrophils, isolated from subjects
with mild asthma who had supplemented their diet with
BO/EO. Prior studies of dietary supplementation with
GLA have demonstrated a reduction in ex vivo leukotriene
generation in whole blood or neutrophils stimulated with
calcium ionophore A23187 or with zymosan [13,26,27].
Basophils [28], IgE [29], and cysteinyl leukotrienes [30]
have been strongly implicated in the pathobiology of
asthma. We therefore assessed the effects of BO/EO com-
binations on the generation of cysteinyl leukotrienes from
basophils stimulated through the high affinity IgE re-
ceptor, a physiologically relevant stimulus for asthma.
Significant inhibition of basophil cysteinyl leukotriene
generation was noted within one week of dietary supple-
mentation (Figure 4). Interestingly, the time dependence
of this inhibition varied between groups. The least robust
inhibition was observed in Group 4, in which subjects re-
ceived the lowest dose of SDA. Although there is consid-
erable variation in the extent of inhibition of ex vivo
leukotriene generation among individuals and the groups
were relatively small, the between group variation was sta-
tistically significant. Furthermore, a comparable variation
in supplementation-induced inhibition of leukotriene gen-
eration was observed in response to A23187- stimulation
of neutrophils (Figure 6). The data therefore suggest that
providing SDA in the diet contributed to the extent of in-
hibition of leukotriene generation, consistent with data
showing that dietary supplementation with EPA leads to
inhibition of ex vivo leukotriene generation [31-33].
In a receptor-independent manner, A23187 robustly
stimulates human neutrophils to elicit maximal gener-
ation of LTB4, the product of leukotriene biosynthesis
in neutrophils. Utilization of this stimulus allows an as-
sessment by RP-HPLC of the non-enzymatic degradation
products of the proximal intermediates of leukotriene
biosynthesis. Dietary supplementation with BO/EO
combinations led to a significant inhibition of A23187-
stimulated leukotriene generation (Figure 6) that was
almost as great as the inhibition of basophil cysteinyl leu-
kotriene generation (Figure 4). We recently reported that
dietary supplementation with BO and fish oil led to re-
duced expression of phosphatidylinositol 3-kinase, a key
signaling molecule, in circulating mononuclear cells [15].
It is therefore possible that the inhibition of cysteinyl leu-
kotriene generation that we observed in basophils was
due, at least in part, to inhibition of signaling through
FcεRI. However, the inhibition of leukotriene biosyn-
thesis in neutrophils stimulated through A23187, a re-
ceptor independent stimulus, argues for a more direct
effect of BO and EO on leukotriene biosynthesis.
Conclusion
Our data demonstrate that ingestion of certain combina-
tions of BO and EO increases circulating levels of both
n-6 and n-3, 20–22 carbon PUFAs. Supplementation of
human and animal diets with these fatty acids has been
shown to inhibit metabolism of AA to pro-inflammatory
lipid mediators and ameliorate inflammatory disease
models including asthma, arthritis and coronary artery
disease [34]. These same combinations do not increase
circulating AA levels, as has been observed with BO
alone. Importantly, the observed biochemical changes
occur concomitantly with a reduced capacity of inflam-
matory cells from mild asthmatics supplemented with
BO/EO combinations to produce leukotrienes that have
been illustrated to be important to promoting the asth-
matic response. Consequently, an important next step
would be to determine whether such BO/EO combina-
tions have the capacity to improve clinical symptoms of
asthma.
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